Compare 3M Company (MMM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs Tango Therapeutics Inc. — how do they compare? 3M Company trades at $165.99 (market cap $84.82B), while Tango Therapeutics Inc. trades at $22.2 (market cap $3.74B). The key difference: 3M Company is far larger — about 22.7× Tango Therapeutics Inc.'s market cap, and 3M Company pays a 1.9% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold 3M Company for 169 Days and Tango Therapeutics Inc. for 0 Days on average.
| MMM | TNGX | |
|---|---|---|
Market Cap | $84.82B | $3.74B |
Volume | 2,697,631 | 3,438,781 |
Sector | Industrials | Health |
52-Week High | $183.79 | $32.90 |
52-Week Low | $141.10 | $7.50 |
Typical Hold Time | 169 Days | 0 Days |
Enterprise Value | $94.04B | $2.76B |
Dividend Yield | 1.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
3M (MMM) trades at $162.77, up 1.17% today, showing resilience amid a bearish technical signal. The company delivered three consecutive quarterly EPS beats, with Q2 2026 actual EPS of $2.40 beating the $2.25 estimate. Revenue for 2025 was $24.95B with a net income margin of 11.9%, though down from 2024's 16.98%. Analyst consensus is split evenly between Buy and Hold ratings, with a $191.00 price target suggesting 17% upside. Recent news highlights operational improvements and litigation management progress.
The outlook for MMM is cautiously optimistic, supported by strong earnings performance and strategic initiatives, but weighed by high debt levels and mixed technical indicators. Investment opportunity lies in continued execution on margin expansion and growth in industrial segments, while risks include consumer segment weakness and macroeconomic pressures. The stock's current valuation at a P/E of 28.91 requires sustained earnings growth to justify further appreciation.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
